Population pharmacokinetics and exposure-response modeling for evinacumab in homozygous familial hypercholesterolemia

• Main Authors: Xia Pu (Author), Mark Sale (Author), Feng Yang (Author), Yi Zhang (Author), John D. Davis (Author), Nidal Al‐Huniti (Author)
• Format: Book
• Published: Wiley, 2021-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Evinacumab, an angiopoietin‐like protein 3 (ANGPTL3) inhibitor, has been shown to significantly reduce low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). This work characterized the population pharmacokinetics (PK)/pharmacodynamics...